Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP1 | P53582 | 1/20 | 0.58 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.56 |
| ▸ | HTR1A | P08908 | 4/20 | 0.52 |
| ▸ | HTR2A | P28223 | 4/20 | 0.52 |
| ▸ | HTR2C | P28335 | 4/20 | 0.52 |
| ▸ | HTR7 | P34969 | 4/20 | 0.52 |
| ▸ | DRD3 | P35462 | 3/20 | 0.52 |
| ▸ | DRD2 | P14416 | 2/20 | 0.52 |
| ▸ | HRH1 | P35367 | 1/20 | 0.52 |
| ▸ | HTR2B | P41595 | 1/20 | 0.52 |
| ▸ | ACHE | P22303 | 4/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.49 |
| ▸ | CYP26A1 | O43174 | 2/20 | 0.49 |
| ▸ | DRD4 | P21917 | 3/20 | 0.48 |
| ▸ | MAOB | P27338 | 2/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29620996 | 1.00 | METAP1 (0.58) | METAP1CYP19A1HTR1AHTR2AHTR2C | |
| SCHEMBL10689573 | 0.82 | METAP1 (0.58) | METAP1CYP19A1ACHESIGMAR1CYP26A1 | |
| SCHEMBL10269432 | 0.82 | METAP1 (0.59) | METAP1CYP19A1ACHESIGMAR1CYP26A1 | |
| SCHEMBL3033688 | 0.81 | CYP19A1 (0.77) | METAP1CYP19A1HTR1AACHESIGMAR1 | |
| SCHEMBL27236975 | 0.80 | METAP1 (0.62) | METAP1CYP19A1HTR1AHTR2AHTR2C | |
| SCHEMBL257977 | 0.79 | CYP19A1 (0.52) | CYP19A1ACHESIGMAR1CYP26A1MAOB | |
| SCHEMBL5582351 | 0.79 | CYP19A1 (0.77) | METAP1CYP19A1ACHECYP26A1 | |
| SCHEMBL12030974 | 0.79 | CYP19A1 (0.52) | CYP19A1ACHESIGMAR1CYP26A1MAOB | |
| SCHEMBL16142397 | 0.78 | METAP1 (0.64) | METAP1CYP19A1HTR1AHTR2AHTR2C | |
| SCHEMBL17147681 | 0.78 | ACHE (0.56) | CYP19A1ACHEMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1423359-B1 | C2-DISUBSTITUTED INDANE-1-ONES AND THEIR DERIVATIVES, METHOD FOR THEIR PRODUCTION AND THEIR USE AS MEDICAMENTS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2010-07-14 | — | — | EP | disclosed |
| US-7081467-B2 | C2-disubstituted indan-1-ones and their derivatives, processes for their preparation and their use as pharmaceuticals | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2006-07-25 | — | — | US | disclosed |
| EP-1423359-A1 | C2-DISUBSTITUTED INDANE-1-ONES AND THEIR DERIVATIVES, METHOD FOR THEIR PRODUCTION AND THEIR USE AS MEDICAMENTS | Aventis Pharma Deutschland GmbH (DE) | 2004-06-02 | — | — | EP | disclosed |
| US-20030153609-A1 | C2-disubstituted indan-1-ones and their derivatives, processes for their preparation and their use as pharmaceuticals | AVENTIS PHARMA DUTSCHLAN GMBH. | 2003-08-14 | — | — | US | disclosed |
| WO-2003020697-A1 | C2-DISUBSTITUTED INDANE-1-ONES AND THEIR DERIVATIVES, METHOD FOR THEIR PRODUCTION AND THEIR USE AS MEDICAMENTS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030153609-A1 | C2-disubstituted indan-1-ones and their derivatives, processes for their preparation and their use as pharmaceuticals | GPR119, INSR, IRS1 | METAP1 775/4885CYP19A1 98/4885HTR1A 1176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.